Dacarbazine hydrochloride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 581183

CAS#: 17925-90-5

Description: Dacarbazine, also known as imidazole carboxamide, is a chemotherapy medication used in the treatment of melanoma and Hodgkin's lymphoma. For Hodgkin's it is often used together with vinblastine, bleomycin, and doxorubicin.


Chemical Structure

img
Dacarbazine hydrochloride
CAS# 17925-90-5

Theoretical Analysis

MedKoo Cat#: 581183
Name: Dacarbazine hydrochloride
CAS#: 17925-90-5
Chemical Formula: C6H11ClN6O
Exact Mass: 218.0683
Molecular Weight: 218.65
Elemental Analysis: C, 32.96; H, 5.07; Cl, 16.21; N, 38.44; O, 7.32

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Dacarbazine hydrochloride; Dacarbazine HCl;

IUPAC/Chemical Name: 5-(3,3-Dimethyl-1-triazeno)-1H-imidazole-4-carboxamide monohydrochloride

InChi Key: JTLLDOORGJVYPT-ASTDGNLGSA-N

InChi Code: InChI=1S/C6H10N6O.ClH/c1-12(2)11-10-6-4(5(7)13)8-3-9-6;/h3H,1-2H3,(H2,7,13)(H,8,9);1H/b11-10+;

SMILES Code: O=C(C1=C(/N=N/N(C)C)NC=N1)N.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 218.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Xiao Y, Liu J, Liu YC, Huang XE, Guo JX, Wei W. Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Asian Pac J Cancer Prev. 2014;15(9):3951-4. PubMed PMID: 24935579.

2: Maafi M, Lee LY. Determination of Dacarbazine Φ-Order Photokinetics, Quantum Yields, and Potential for Actinometry. J Pharm Sci. 2015 Oct;104(10):3501-9. doi: 10.1002/jps.24568. Epub 2015 Jul 14. PubMed PMID: 26173629.

3: Trissel LA, Zhang Y, Xu QA. Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated y-site administration. Int J Pharm Compd. 2006 May-Jun;10(3):234-6. PubMed PMID: 23974237.

4: Nitta Y, Ikeya T, Sakakibara A, Tomita Y. Therapy-related myelodysplastic syndrome developed by dacarbazine, nimustine hydrochloride and vincristine sulfate (DAV) therapy for patient with malignant melanoma. J Dermatol. 2011 Feb;38(2):164-8. doi: 10.1111/j.1346-8138.2010.00947.x. Epub 2010 Nov 11. PubMed PMID: 21269313.

5: Lunn G, Sansone EB. Reductive destruction of dacarbazine, procarbazine hydrochloride, isoniazid, and iproniazid. Am J Hosp Pharm. 1987 Nov;44(11):2519-24. PubMed PMID: 3687991.

6: Stewart JT, Warren FW, King DT, Venkateshwaran TG, Ponder GW, Fox JL. Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags. Am J Health Syst Pharm. 1997 Apr 15;54(8):915-20. PubMed PMID: 9114924.

7: Yamazaki N, Yamamoto A, Wada T, Ishikawa M. Dacarbazine, nimustine hydrochloride, cisplatin and tamoxifen combination chemotherapy for advanced malignant melanoma. J Dermatol. 1999 Aug;26(8):489-93. PubMed PMID: 10487002.

8: Clarke JL, Molinaro AM, Phillips JJ, Butowski NA, Chang SM, Perry A, Costello JF, DeSilva AA, Rabbitt JE, Prados MD. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. Neuro Oncol. 2014 Jul;16(7):984-90. PubMed PMID: 24637230; PubMed Central PMCID: PMC4057142.

9: Sperduto PW, Wang M, Robins HI, Schell MC, Werner-Wasik M, Komaki R, Souhami L, Buyyounouski MK, Khuntia D, Demas W, Shah SA, Nedzi LA, Perry G, Suh JH, Mehta MP. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1312-8. doi: 10.1016/j.ijrobp.2012.11.042. Epub 2013 Feb 4. PubMed PMID: 23391814; PubMed Central PMCID: PMC3740376.

10: Wilisch-Neumann A, Pachow D, Wallesch M, Petermann A, Böhmer FD, Kirches E, Mawrin C. Re-evaluation of cytostatic therapies for meningiomas in vitro. J Cancer Res Clin Oncol. 2014 Aug;140(8):1343-52. doi: 10.1007/s00432-014-1683-6. Epub 2014 May 11. PubMed PMID: 24816784.

11: Takata Y, Hayashi S, Ohno T, Dekio S. Paralytic ileus associated with a combination of dacarbazine-nimustine hydrochloride-vincristine chemotherapy. J Dermatol. 1997 Oct;24(10):682-3. PubMed PMID: 9375471.

12: Tanaka S, Akimoto J, Narita Y, Oka H, Tashiro T. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide? J Neurosurg. 2014 Oct;121(4):818-26. doi: 10.3171/2014.6.JNS132535. Epub 2014 Aug 8. PubMed PMID: 25105699.

13: Jotte RM, Von Hoff DD, Braiteh F, Becerra CR, Richards DA, Smith DA, Garbo L, Stephenson J, Conkling PR, Robert-Vizcarrondo F, Chen J, Turner PK, Chow KH, Tai DF, Ilaria R Jr. An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors. Invest New Drugs. 2015 Feb;33(1):148-58. doi: 10.1007/s10637-014-0160-z. Epub 2014 Sep 28. PubMed PMID: 25260842.

14: Wen Q, Jalilian L, Lupo JM, Molinaro AM, Chang SM, Clarke J, Prados M, Nelson SJ. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab. J Neurooncol. 2015 Jan;121(2):331-9. doi: 10.1007/s11060-014-1636-6. Epub 2014 Oct 29. PubMed PMID: 25351579; PubMed Central PMCID: PMC4311062.

15: Kawano H, Hirano H, Yonezawa H, Yunoue S, Yatsushiro K, Ogita M, Hiraki Y, Uchida H, Habu M, Fujio S, Oyoshi T, Bakhtiar Y, Sugata S, Yamahata H, Hanaya R, Tokimura H, Arita K. Improvement in treatment results of glioblastoma over the last three decades and beneficial factors. Br J Neurosurg. 2015 Apr;29(2):206-12. doi: 10.3109/02688697.2014.967750. Epub 2014 Oct 14. PubMed PMID: 25311043.

16: Mizumoto M, Yamamoto T, Takano S, Ishikawa E, Matsumura A, Ishikawa H, Okumura T, Sakurai H, Miyatake S, Tsuboi K. Long-term survival after treatment of glioblastoma multiforme with hyperfractionated concomitant boost proton beam therapy. Pract Radiat Oncol. 2015 Jan-Feb;5(1):e9-16. doi: 10.1016/j.prro.2014.03.012. Epub 2014 May 19. PubMed PMID: 25413424.

17: Mizumoto M, Yamamoto T, Ishikawa E, Matsuda M, Takano S, Ishikawa H, Okumura T, Sakurai H, Matsumura A, Tsuboi K. Proton beam therapy with concurrent chemotherapy for glioblastoma multiforme: comparison of nimustine hydrochloride and temozolomide. J Neurooncol. 2016 Oct;130(1):165-170. Epub 2016 Aug 17. PubMed PMID: 27535747.

18: Marchi E, Vargas FS, Teixeira LR, Fagundes DJ, Silva LM, Carmo AO, Light RW. Comparison of nitrogen mustard, cytarabine and dacarbazine as pleural sclerosing agents in rabbits. Eur Respir J. 1997 Mar;10(3):598-602. PubMed PMID: 9072991.

19: Avivi I, Hardak E, Shaham B, Igla M, Rowe JM, Dann EJ. Low incidence of long-term respiratory impairment in Hodgkin lymphoma survivors. Ann Hematol. 2012 Feb;91(2):215-21. doi: 10.1007/s00277-011-1255-7. Epub 2011 May 21. PubMed PMID: 21603918.

20: Brentuximab Vedotin in Combination With Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study. Clin Adv Hematol Oncol. 2016 Feb;14(2 Suppl 1):13-5. PubMed PMID: 27007006.